BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34884309)

  • 1. Combined Inhibition of Bcl2 and Bcr-Abl1 Exercises Anti-Leukemia Activity but Does Not Eradicate the Primitive Leukemic Cells.
    Massimino M; Vigneri P; Stella S; Tirrò E; Pennisi MS; Parrinello LN; Vetro C; Manzella L; Stagno F; Di Raimondo F
    J Clin Med; 2021 Nov; 10(23):. PubMed ID: 34884309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High
    Massimino M; Stella S; Tirrò E; Pennisi MS; Stagno F; Vitale SR; Romano C; Tomarchio C; Parrinello NL; Manzella L; Di Raimondo F; Vigneri P
    Onco Targets Ther; 2023; 16():803-816. PubMed ID: 37807980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting BCL-2 as a Therapeutic Strategy for Primary
    Massimino M; Tirrò E; Stella S; Pennisi MS; Vitale SR; Puma A; Romano C; DI Gregorio S; Romeo MA; DI Raimondo F; Manzella L
    In Vivo; 2020; 34(2):511-516. PubMed ID: 32111748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors.
    Corbin AS; O'Hare T; Gu Z; Kraft IL; Eiring AM; Khorashad JS; Pomicter AD; Zhang TY; Eide CA; Manley PW; Cortes JE; Druker BJ; Deininger MW
    Cancer Res; 2013 Sep; 73(18):5775-86. PubMed ID: 23887971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.
    Neviani P; Harb JG; Oaks JJ; Santhanam R; Walker CJ; Ellis JJ; Ferenchak G; Dorrance AM; Paisie CA; Eiring AM; Ma Y; Mao HC; Zhang B; Wunderlich M; May PC; Sun C; Saddoughi SA; Bielawski J; Blum W; Klisovic RB; Solt JA; Byrd JC; Volinia S; Cortes J; Huettner CS; Koschmieder S; Holyoake TL; Devine S; Caligiuri MA; Croce CM; Garzon R; Ogretmen B; Arlinghaus RB; Chen CS; Bittman R; Hokland P; Roy DC; Milojkovic D; Apperley J; Goldman JM; Reid A; Mulloy JC; Bhatia R; Marcucci G; Perrotti D
    J Clin Invest; 2013 Oct; 123(10):4144-57. PubMed ID: 23999433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repurposing the Bis-Biguanide Alexidine in Combination with Tyrosine Kinase Inhibitors to Eliminate Leukemic Stem/Progenitor Cells in Chronic Myeloid Leukemia.
    Muselli F; Mourgues L; Rochet N; Nebout M; Guerci A; Verhoeyen E; Krug A; Legros L; Peyron JF; Mary D
    Cancers (Basel); 2023 Feb; 15(3):. PubMed ID: 36765952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.
    Pietarinen PO; Eide CA; Ayuda-Durán P; Potdar S; Kuusanmäki H; Andersson EI; Mpindi JP; Pemovska T; Kontro M; Heckman CA; Kallioniemi O; Wennerberg K; Hjorth-Hansen H; Druker BJ; Enserink JM; Tyner JW; Mustjoki S; Porkka K
    Oncotarget; 2017 Apr; 8(14):22606-22615. PubMed ID: 28186983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A kinase profile-adapted drug combination elicits synergistic cooperative effects on leukemic cells carrying BCR-ABL1
    Gleixner KV; Sadovnik I; Schneeweiss M; Eisenwort G; Byrgazov K; Stefanzl G; Berger D; Herrmann H; Hadzijusufovic E; Lion T; Valent P
    Leuk Res; 2019 Mar; 78():36-44. PubMed ID: 30711891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-Mediated Targeted Protein Degradation.
    Burslem GM; Schultz AR; Bondeson DP; Eide CA; Savage Stevens SL; Druker BJ; Crews CM
    Cancer Res; 2019 Sep; 79(18):4744-4753. PubMed ID: 31311809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Involvement of Rho-Associated Coiled-Coil Containing Kinase (ROCK) in BCR-ABL1 Tyrosine Kinase Inhibitor Cardiovascular Toxicity.
    Yu B; Osman AEG; Sladojevic N; Prabhu N; Tai HC; Chen D; Perla G; Park L; Larson RA; Liao JK
    JACC CardioOncol; 2022 Sep; 4(3):371-383. PubMed ID: 36213346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Developments in Chronic Myeloid Leukemia: Implications for Therapy.
    Tabarestani S; Movafagh A
    Iran J Cancer Prev; 2016 Feb; 9(1):e3961. PubMed ID: 27366312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the tyrosine kinase inhibitor AG957 and an Anti-Fas receptor antibody on CD34(+) chronic myelogenous leukemia progenitor cells.
    Carlo-Stella C; Regazzi E; Sammarelli G; Colla S; Garau D; Gazit A; Savoldo B; Cilloni D; Tabilio A; Levitzki A; Rizzoli V
    Blood; 1999 Jun; 93(11):3973-82. PubMed ID: 10339507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting STAT5 or STAT5-Regulated Pathways Suppresses Leukemogenesis of Ph+ Acute Lymphoblastic Leukemia.
    Minieri V; De Dominici M; Porazzi P; Mariani SA; Spinelli O; Rambaldi A; Peterson LF; Porcu P; Nevalainen MT; Calabretta B
    Cancer Res; 2018 Oct; 78(20):5793-5807. PubMed ID: 30154155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia.
    Srutova K; Curik N; Burda P; Savvulidi F; Silvestri G; Trotta R; Klamova H; Pecherkova P; Sovova Z; Koblihova J; Stopka T; Perrotti D; Polakova KM
    Haematologica; 2018 Dec; 103(12):2016-2025. PubMed ID: 30049824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of isoprenylcysteine carboxylmethyltransferase augments BCR-ABL1 tyrosine kinase inhibition-induced apoptosis in chronic myeloid leukemia.
    Sun WT; Xiang W; Ng BL; Asari K; Bunte RM; Casey PJ; Wang M; Chuah C
    Exp Hematol; 2016 Mar; 44(3):189-93.e2. PubMed ID: 26706195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical
    Massimino M; Tirrò E; Stella S; Manzella L; Pennisi MS; Romano C; Vitale SR; Puma A; Tomarchio C; Di Gregorio S; Antolino A; Di Raimondo F; Vigneri P
    Front Pharmacol; 2021; 12():669469. PubMed ID: 34276365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multifaceted mechanisms for cell survival and drug targeting in chronic myelogenous leukemia.
    Kuroda J; Shimura Y; Yamamoto-Sugitani M; Sasaki N; Taniwaki M
    Curr Cancer Drug Targets; 2013 Jan; 13(1):69-79. PubMed ID: 22414011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia.
    Gleixner KV; Schneeweiss M; Eisenwort G; Berger D; Herrmann H; Blatt K; Greiner G; Byrgazov K; Hoermann G; Konopleva M; Waliul I; Cumaraswamy AA; Gunning PT; Maeda H; Moriggl R; Deininger M; Lion T; Andreeff M; Valent P
    Haematologica; 2017 Sep; 102(9):1519-1529. PubMed ID: 28596283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1
    Mian AA; Haberbosch I; Khamaisie H; Agbarya A; Pietsch L; Eshel E; Najib D; Chiriches C; Ottmann OG; Hantschel O; Biondi RM; Ruthardt M; Mahajna J
    Ann Hematol; 2021 Aug; 100(8):2023-2029. PubMed ID: 34110462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneous BCR-ABL1 signal patterns identified by fluorescence in situ hybridization are associated with leukemic clonal evolution and poorer prognosis in BCR-ABL1 positive leukemia.
    Zhang Z; Chen Z; Jiang M; Liu S; Guo Y; Wan L; Li F
    BMC Cancer; 2019 Oct; 19(1):935. PubMed ID: 31594548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.